查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387502

T 细胞淋巴瘤市场报告：2030 年趋势、预测与竞争分析

T-Cell Lymphoma Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

T细胞淋巴瘤的趋势和预测

预计到 2030 年，全球 T 细胞淋巴瘤市场将达到 33 亿美元，2024 年至 2030 年年复合成长率为 6.5%。该市场的主要驱动因素是全球T细胞淋巴瘤盛行率的上升、癌症治疗技术的进步以及包括CAR-T细胞疗法和免疫检查点抑制剂在内的免疫疗法的使用增加。全球T细胞淋巴瘤市场前景广阔，放射线治疗、化疗、免疫治疗、干细胞移植市场充满机会。

T 细胞淋巴瘤市场洞察

Lucintel 预测，週边 T 细胞淋巴瘤将在预测期内出现最高成长。这是因为它在儿童和年轻人中更为常见，儘管它是一种生长缓慢的淋巴瘤，但可能很难治疗。

由于 T 细胞淋巴瘤的高盛行率、主要行业参与企业的存在以及高研发活动，预计北美在预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 未来哪个细分市场成长较快？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球T细胞淋巴瘤市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球T细胞淋巴瘤市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球 T 细胞淋巴瘤市场
    • 週边T细胞淋巴瘤
    • 皮肤T细胞淋巴瘤
    • 异生性大细胞淋巴瘤
    • 血管免疫母细胞T细胞淋巴瘤
  • 按治疗分類的全球 T 细胞淋巴瘤市场
    • 放射线治疗
    • 化疗
    • 免疫疗法
    • 干细胞移植
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 按地区分類的全球 T 细胞淋巴瘤市场
  • 北美T细胞淋巴瘤市场
  • 欧洲T细胞淋巴瘤市场
  • 亚太地区T细胞淋巴瘤市场
  • 其他地区T细胞淋巴瘤市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球 T 细胞淋巴瘤市场成长机会
    • 全球 T 细胞淋巴瘤治疗市场成长机会
    • 全球 T 细胞淋巴瘤市场成长机会（按地区）
  • 全球T细胞淋巴瘤市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球 T 细胞淋巴瘤市场的产能
    • 全球T细胞淋巴瘤市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Johnson & Johnson
  • Novartis
  • Bristol Myers Squibb Company
  • Merck
  • F. Hoffmann-La Roche
简介目录

T-Cell Lymphoma Trends and Forecast

The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets. The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.

A more than 150-page report is developed to help in your business decisions.

T-Cell Lymphoma by Segment

The study includes a forecast for the global T-cell lymphoma by type, therapy, and region.

T-Cell Lymphoma Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Peripheral T-Cell Lymphoma
  • Cutaneous T-Cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angio-Immuno-Blastic T-Cell Lymphoma

T-Cell Lymphoma Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

T-Cell Lymphoma Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of T-Cell Lymphoma Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies T-cell lymphoma companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the T-cell lymphoma companies profiled in this report include-

  • Johnson & Johnson
  • Novartis
  • Bristol Myers Squibb Company
  • Merck
  • F. Hoffmann-La Roche

T-Cell Lymphoma Market Insights

Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.

North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.

Features of the Global T-Cell Lymphoma Market

Market Size Estimates: T-cell lymphoma market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: T-cell lymphoma market size by type, therapy, and region in terms of value ($B).

Regional Analysis: T-cell lymphoma market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, therapy, and regions for the T-cell lymphoma market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the T-cell lymphoma market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the T-cell lymphoma market size?

Answer: The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030.

Q2. What is the growth forecast for T-cell lymphoma market?

Answer: The global T-cell lymphoma market is expected to grow with a CAGR of 6.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the T-cell lymphoma market?

Answer: The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.

Q4. What are the major segments for T-cell lymphoma market?

Answer: The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets.

Q5. Who are the key T-cell lymphoma market companies?

Answer: Some of the key T-cell lymphoma companies are as follows:

  • Johnson & Johnson
  • Novartis
  • Bristol Myers Squibb Company
  • Merck
  • F. Hoffmann-La Roche

Q6. Which T-cell lymphoma market segment will be the largest in future?

Answer: Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.

Q7. In T-cell lymphoma market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the T-cell lymphoma market by type (peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angio-immuno-blastic T-cell lymphoma), therapy (radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global T-Cell Lymphoma Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global T-Cell Lymphoma Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global T-Cell Lymphoma Market by Type
    • 3.3.1: Peripheral T-cell Lymphoma
    • 3.3.2: Cutaneous T-cell Lymphoma
    • 3.3.3: Anaplastic Large Cell Lymphoma
    • 3.3.4: Angio-Immuno-blastic T-cell Lymphoma
  • 3.4: Global T-Cell Lymphoma Market by Therapy
    • 3.4.1: Radiotherapy
    • 3.4.2: Chemotherapy
    • 3.4.3: Immunotherapy
    • 3.4.4: Stem Cell Transplantation
    • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global T-Cell Lymphoma Market by Region
  • 4.2: North American T-Cell Lymphoma Market
    • 4.2.2: North American T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
  • 4.3: European T-Cell Lymphoma Market
    • 4.3.1: European T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
    • 4.3.2: European T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
  • 4.4: APAC T-Cell Lymphoma Market
    • 4.4.1: APAC T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
    • 4.4.2: APAC T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
  • 4.5: ROW T-Cell Lymphoma Market
    • 4.5.1: ROW T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
    • 4.5.2: ROW T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global T-Cell Lymphoma Market by Type
    • 6.1.2: Growth Opportunities for the Global T-Cell Lymphoma Market by Therapy
    • 6.1.3: Growth Opportunities for the Global T-Cell Lymphoma Market by Region
  • 6.2: Emerging Trends in the Global T-Cell Lymphoma Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global T-Cell Lymphoma Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global T-Cell Lymphoma Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Novartis
  • 7.3: Bristol Myers Squibb Company
  • 7.4: Merck
  • 7.5: F. Hoffmann-La Roche